Sally Pipes: Trump’s socialist price controls will harm patients | TribLIVE.com
Featured Commentary

Sally Pipes: Trump’s socialist price controls will harm patients

1569308_web1_gtr-cmns-Pipes-082219
Pixabay

The Trump administration is planning one of the biggest changes to Medicare in decades.

The draft rule would effectively bring socialist drug price controls to the United States. The change would threaten patients’ health and discourage companies from funding experimental treatments for deadly diseases.

The rule impacts Medicare Part B, which covers drugs administered via shots and IV drips in hospitals and doctor’s offices. Most cancer treatments, for instance, are covered through Part B.

Part B drugs cost more in America than in countries like Canada and the United Kingdom, which impose strict price controls on prescription drugs. If bureaucratic agencies — such as Canada’s Patented Medicine Prices Review Board — deem a drug too expensive, they refuse to cover it.

Apparently, the Trump administration thinks these countries have the right idea. Officials believe that tying Medicare reimbursements to the average prices paid for drugs in a handful of foreign countries, where price controls are common, would reduce Part B drug spending.

Americans have little to gain and much to lose from statist price controls.

Drug development is risky. It can take decades and cost a staggering $2.9 billion to develop a new medicine. Most experimental drugs never even make it out of the lab. Manufacturers fund future research with the revenue from just a handful of successful products.

The rule would make drug development far less appealing. If the potential return on investment were capped, companies would have little reason to spend billions trying to develop new medicines.

History shows us what happens to drug development when price controls are employed. Europe was a hotbed of drug innovation in the 1970s, producing over half all drugs worldwide. But European nations gradually ramped up price controls in the ensuing decades.

U.S. leaders resisted that temptation — which explains why America now attracts 75% of global biopharmaceutical venture capital investments and develops more than half of the world’s medicines, while Europe invents a mere third of drugs.

Price controls may yield some short-term savings, but they would cost patients dearly in the long run.

Sally Pipes is president, CEO and Thomas W. Smith Fellow in Health Care Policy at the Pacific Research Institute. Her latest book is “The False Promise of Single-Payer Health Care.” Follow her on Twitter @sallypipes.

TribLIVE commenting policy

You are solely responsible for your comments and by using TribLive.com you agree to our Terms of Service.

We moderate comments. Our goal is to provide substantive commentary for a general readership. By screening submissions, we provide a space where readers can share intelligent and informed commentary that enhances the quality of our news and information.

While most comments will be posted if they are on-topic and not abusive, moderating decisions are subjective. We will make them as carefully and consistently as we can. Because of the volume of reader comments, we cannot review individual moderation decisions with readers.

We value thoughtful comments representing a range of views that make their point quickly and politely. We make an effort to protect discussions from repeated comments either by the same reader or different readers

We follow the same standards for taste as the daily newspaper. A few things we won't tolerate: personal attacks, obscenity, vulgarity, profanity (including expletives and letters followed by dashes), commercial promotion, impersonations, incoherence, proselytizing and SHOUTING. Don't include URLs to Web sites.

We do not edit comments. They are either approved or deleted. We reserve the right to edit a comment that is quoted or excerpted in an article. In this case, we may fix spelling and punctuation.

We welcome strong opinions and criticism of our work, but we don't want comments to become bogged down with discussions of our policies and we will moderate accordingly.

We appreciate it when readers and people quoted in articles or blog posts point out errors of fact or emphasis and will investigate all assertions. But these suggestions should be sent via e-mail. To avoid distracting other readers, we won't publish comments that suggest a correction. Instead, corrections will be made in a blog post or in an article.